Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05189223 · ClinicalTrials.gov registry record · NA

A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment

A NA study of Dependence, Opioid, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05189223 is a NA study of Dependence, Opioid that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05189223, a NA study of Dependence, Opioid, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The US Veteran community continues to feel the impact of the overdose crisis, and opioid use disorder (OUD) diagnoses among Veterans continue to rise. Medication treatment (e.g., buprenorphine, methadone, naltrexone) helps prevent relapse and reduce overdose risk, but does not help with the psychological, social, and functional challenges of early recovery. Therapies that focus on interpersonal functioning and community integration may help improve quality of life during this high-risk period. This research project will create and test a brief, values-based treatment to help Veterans improve their interpersonal functioning and community integration during early treatment. This study will have three phases. Phase 1 will involve the development of the treatment and adaptation using interviews with Veterans and VA Providers. Phase 2 will test the treatment with a group of 10 Veterans to make sure the treatment can be delivered as intended, and to make changes to the treatment or study procedures based on Veteran feedback. Finally, Phase 3 will test the treatment compared to usual treatment in a pilot randomized controlled trial with a group of 40 Veterans. This final phase will provide additional information about Veterans' experience of the treatment and study procedures and the preliminary effects of the treatment on quality of life and related outcomes.

Conditions Studied

Interventions

  • BEHAVIORAL Treatment as Usual
  • BEHAVIORAL Brief, values based intervention for early buprenorphine treatment

Study Locations (1)

Massachusetts

  • VA Bedford HealthCare System, Bedford, MA - Bedford

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-09-01
Est. Completion 2027-03-31
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT05189223

The ClinicalTrials.gov registry entry for NCT05189223 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dependence, Opioid appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT05189223 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05189223 about?

NCT05189223 is a clinical study titled "A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment". The US Veteran community continues to feel the impact of the overdose crisis, and opioid use disorder (OUD) diagnoses among Veterans continue to rise. Medication treatment (e.g., buprenorphine, methadone, naltrexone) helps prevent relapse and reduce overdose risk, but does not help with the psycholo...

What is the current status of trial NCT05189223?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2023-09-01. Estimated completion is 2027-03-31.

What conditions does trial NCT05189223 study?

This clinical trial studies the following conditions: Dependence, Opioid.

What interventions are being tested in trial NCT05189223?

The interventions under investigation include: Treatment as Usual (BEHAVIORAL), Brief, values based intervention for early buprenorphine treatment (BEHAVIORAL).

Who is sponsoring clinical trial NCT05189223?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05189223 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.